Global Archives – Page 14 of 26 – Treatment Action Group

HIV Science Fact Sheet

October 26, 2021
Dorrit Walsh

HIV science can be difficult to understand. This handout explains some of the unique scientific challenges presented by HIV. The handout was developed in collaboration with the Black AIDS Institute, HIV Vaccine Trials Network, and Southern AIDS Coalition.

Statement from TAG’s TB Project on Today’s WHO Global TB Report

October 14, 2021
Dorrit Walsh

Today's Global TB Report from WHO confirms our worst expectations for how COVID-19 has set back the global TB response. The pandemic has reversed an entire generation of progress. The first year-on-year increase in TB deaths since 2005 is devastating.

Long-Acting Therapy for Malaria Prevention: Toward a Malaria-Free World

October 6, 2021
Dorrit Walsh

By Joelle Dountio Ofimboudem Malaria is a life-threatening disease prevalent in the world’s poorest countries, particularly in sub-Saharan Africa. Preventing malaria hits close to home for me. I am a mother to two children, aged three and five. We are…

Delivering on the Promise of Long-Acting Technologies

October 3, 2021
Dorrit Walsh

By Susan Swindells* and Mark Harrington This issue of TAGline explores the exciting opportunities and challenges that come with the development of long-acting formulations for the prevention and treatment of infectious diseases. For many years to date, patients and providers…

A Partnership to Expand Access to Lifesaving Testing and Treatment for Hepatitis C

September 20, 2021
Dorrit Walsh

Hepatitis C PACT was launched in 2021 and aims to tackle ongoing disparities in access to diagnostics and treatment for hepatitis C virus (HCV) in low-and middle-income countries (LMICs), home to 75% of people living with the viral illness. This brief explains the group's goals and work.

first page of TAG and MSF brief: Realizing returns on U.S. government investment in GeneXpert Diagnostic Technologies

Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies

September 15, 2021
Dorrit Walsh

GeneXpert diagnostic tests are essential tools in the struggle against COVID-19, tuberculosis, HIV, viral hepatitis, and other diseases. This brief outlines actionable steps the U.S. government can take to hold Cepheid accountable for transparent, fair, and equitable pricing of GeneXpert tests.

Have a Heart, Save My Liver! Who Has Access to the Cure in Africa?

September 11, 2021
Dorrit Walsh

On September 11 2021, Treatment Action Group’s Joelle Dountio Ofinboudem presented new data on the registration of the hepatitis C cure at the Conference on Liver Disease in Africa (COLDA) 2021. The presentation titled, “Have a Heart, Save My Liver! Who Has Access to the Cure in Africa,” explains that accelerating treatment uptake across Africa is urgently needed to meet WHO hepatitis C targets by 2030.

Substantial Public Investments in GeneXpert Underscore Need for Affordable Pricing

August 27, 2021
Dorrit Walsh

TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.

Long-Acting Technologies Resource Compendium

July 28, 2021
Dorrit Walsh

Our resource compendium is a non-exhaustive list of materials covering long-acting technologies to inform the hepatitis C, latent tuberculosis infection, and malaria scope of work under the LONGEVITY Project. Long-Acting Technologies Trials Tracker Illustrated Glossary for Long-Acting Technologies Select Scientific…

Illustrated Glossary for Long-Acting Technologies

July 28, 2021
Dorrit Walsh

The Illustrated Glossary for Long-Acting Technologies compiles frequent terms and concepts used in the research and development of long-acting technologies. The glossary is a non-exhaustive list and the graphics are artistic renderings meant to spur discussion and assist with community treatment literacy.